New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 14, 2014
09:11 EDTVIPS, ENPH, RHHBY, DDD, XONE, PRGO, ARUN, SNY, SSYS, PLUG, KBIO, SUPN, NDLS, ITMN, VJET, KSSOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Kohl's (KSS), up 2.5%... Plug Power (PLUG), up 10%... Perrigo (PRGO), up 4.5%. HIGHER: Aruba Networks (ARUN), up 3% after shares upgraded at Stifel... KaloBios (KBIO), up 7.9% after publication shows EphA3 as target for anticancer therapy... Supernus (SUPN), up 4.4% after receiving FDA fast track designation for SPN-810. DOWN AFTER EARNINGS: Noodles & Company (NDLS), down 22%... Vipshop (VIPS), down 5.8%. LOWER: ExOne (XONE), down 10.7%, Voxeljet (VJET), down 6.6%, after earnings reports. Peers in the 3D space are lower as well, with Stratasys (SSYS) down 1% and 3D Systems (DDD) down 0.2%... Enphase Energy (ENPH), down 2.6% after filing to sell common stock for holders... InterMune (ITMN), down 3% after downgraded at Goldman following yesterday's advance on Bloomberg report that the company received takeover bids from Sanofi (SNY), Roche (RHHBY).
News For KSS;PLUG;XONE;VJET;SSYS;DDD;ITMN;SNY;RHHBY;NDLS;ARUN;ENPH;SUPN;PRGO;VIPS;KBIO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
November 18, 2014
09:03 EDTKSSKohl's has light at end of tunnel, says Sterne Agee
Subscribe for More Information
07:30 EDTNDLSMorgan Stanley to hold a conference
Subscribe for More Information
November 17, 2014
13:12 EDTVJET, SSYS, DDD3D Systems rises after insider buy, Voxeljet slips after downgrade
Subscribe for More Information
12:29 EDTVJETVoxeljet downgraded to Market Perform at Cowen
Cowen downgraded Voxeljet to Market Perform from Outperform citing the company's larger than expected Q3 loss and reduced 2014 outlook. The firm cut its price target for shares to $13 from $22.
12:20 EDTVJETVoxeljet downgraded to Market Perform from Outperform at Cowen
Subscribe for More Information
11:28 EDTARUNAruba Networks Q1 sales likely ahead of expectations, says Piper Jaffray
Subscribe for More Information
10:38 EDTSSYSStratasys announces partnership with Martha Stewart Living Omnimedia
Subscribe for More Information
09:57 EDTDDD3D Systems up 3.5% in early trading following Chairman stock purchase
Subscribe for More Information
07:49 EDTARUNAruba Networks estimates appear achievable, says UBS
UBS remains a buyer of Aruba Networks ahead of its Q1 results, as the firm sees improving operational discipline and cost cutting, continuation of its product cycle, free cash flow, and new partnerships. UBS reiterated its Buy rating and $25 price target on Aruba Networks shares.
07:16 EDTSNYMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
05:30 EDTRHHBYInovio, Roche terminate collaboration for INO-5150
Subscribe for More Information
November 16, 2014
14:44 EDTSNYRegulus, Sanofi present new data enhancing the preclinical profile of RG-012
Subscribe for More Information
12:56 EDTSNYGenzyme’s Lemtrada approved by the FDA
Genzyme, a Sanofi company, announced that the U.S. Food and Drug Administration has approved Lemtrada, alemtuzumab, for the treatment of patients with relapsing forms of multiple sclerosis. Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS. “Today’s approval is the culmination of more than a decade of work by Genzyme to develop Lemtrada,” said Genzyme President and CEO, David Meeker. “Lemtrada demonstrated superior efficacy over Rebif on annualized relapse rates in the two studies which were the basis for approval. A comprehensive risk evaluation and mitigation strategy will be instituted in order to help detect and manage the serious risks identified with treatment.” The FDA approval of Lemtrada is based on two pivotal randomized Phase III open-label rater-blinded studies comparing treatment with Lemtrada to Rebif in patients with relapsing remitting MS who were either new to treatment or who had relapsed while on prior therapy . In CARE-MS I, Lemtrada was significantly more effective than interferon beta-1a at reducing annualized relapse rates; the difference observed in slowing disability progression did not reach statistical significance. In CARE-MS II, Lemtrada was significantly more effective than interferon beta-1a at reducing annualized relapse rates, and accumulation of disability was significantly slowed in patients given Lemtrada vs. interferon beta-1a. The clinical development program for Lemtrada involved nearly 1,500 patients with more than 6,400 patient-years of safety follow-up. “The unmet need in MS remains high,” said Edward Fox, M.D., Ph.D., Director of the Multiple Sclerosis Clinic of Central Texas. “It is a great day for people living with relapsing forms of MS in the United States, who will now have access to this new meaningful treatment”.
November 14, 2014
15:12 EDTVJETVoxeljet management to meet with Piper Jaffray
Subscribe for More Information
15:04 EDTVIPSVipshop November volatility elevated into Q3 and outlook
Subscribe for More Information
14:53 EDTSNY, RHHBYCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
13:27 EDTRHHBYRoche reports FDA nod for Avastin in platinum-resistant recurrent ovarian cancer
Subscribe for More Information
10:10 EDTDDDOptions with decreasing implied volatility
Subscribe for More Information
08:33 EDTXONEExOne momentum may improve in 2015, says Oppenheimer
After ExOne reported weaker than expected Q3 results, Oppenheimer says the company was confident that its performance will improve in Q4. The firm thinks that ExOne's 2015 guidance looks conservative, while the company's momentum may improve significantly in 6-12 months. It keeps an Outperform rating on the shares.
08:20 EDTXONEExOne price target lowered to $37 from $45 at FBR Capital
FBR Capital lowered its price target for ExOne shares to $37 saying deferrals impacted the company's Q3 results. The firm keeps an Outperform rating on the stock.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use